Risk factors for coronary heart disease and persistent infection with chlamydia pneumoniae or cytomegalovirus: A population-based study

European Journal of Preventive Cardiology

Volumn 6, Issue 6, 1999, Pages 387-390

  Danesh, John ^a   Wong, Yuk Ki ^b   Ward, Michael ^b   Muir, John ^c  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Chlamydia pneumoniae; chronic infection; coronary heart disease; cytomegalovirus; risk factors

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY RISK; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERSISTENT INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SERODIAGNOSIS; SEX DIFFERENCE;

ADULT; AGE FACTORS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHI-SQUARE DISTRIBUTION; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUESTIONNAIRES; REGRESSION ANALYSIS; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; SMOKING;

EID: 0033402390     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748739900600605     Document Type: Article

References (24)

1. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430–436.
2. Danesh J, Appleby P. Persistent infection and vascular disease: a systematic review. Expert Opin Invest Drugs 1998; 7: 691–713.
3. Danesh J. Coronary heart disease, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus: meta-analyses of prospective studies. Am Heart J 1999; (in press).
4. Gurfinkel E, Bozovich G, Daroca A, Beck A, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancer 1997; 350: 404–407.
5. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J 1999; 20: 121–127.
6. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404–407.
7. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540–1547.
8. Imperial Cancer Research Fund OXCHECK Study Group. Prevalence of risk factors for heart disease in OXCHECK trial: implication for screening in primary care. BMJ 1991; 302: 1057–1060.
9. Danesh J, Wong YK, Ward M, Muir J. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population-based study of coronary heart disease. Heart 1999; 81: 245–247.
10. Wilkins J, Gallimore JR, Tennent GA, Pepys MB. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994; 40: 1284–1290.
11. Wong Y-K, Sueur JM, Fall CHD, Orfila J. Ward ME. The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring antibodies against Chlamydia pneumoniae. J Clin Pathol 1999; 2: 99–103.
12. Grayston JT. Chlamydia pneumoniae, strain TWAR. In: Bowie WR (editor): International symposium on human chlamydial infections. New York: Cambridge University Press; 1990. pp. 389–401.
13. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae–coronary artery disease association. Arterioscler Thromb 1992; 12: 945–947.
14. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994; 23: 1315–1321.
15. O'Neill C, Murray LI, Ong GML, O'Reilly DPJ, Evans AE, Bamford KB. Epidemiology of Chlamydia pneumoniae in a randomly selected population in a developed country. Epidemiol Infect 1999; 122: 111–116.
16. Patel P, Mendall MA, Carrington D, Strachan DP, Leathom E, Molineaux N, et al Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711–714.
17. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levy J, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121–128.
18. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2910–2913.
19. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross sectional study. BMJ 1997; 314: 1456–1457.
20. Cook PJ, Lip GYH, Davis P, Beevers DG, Wise R, Honeybourne D. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589–594.
21. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996; 348 (suppl I): s13–s17.
22. Kaner RJ, Hajjar DP. Viral activation of thrombo-atherosclerosis. In: Fuster V, Ross R, Topol EJ (editors): Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 569–584.
23. Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR, et al High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lanced 987; 11: 291–293.
24. Nieto FJ, Sorlie P, Comstock GW, Wu K, Adam E, Melnick JL, et al Cytomegalovirus infection, lipoprotein(a), and hypercoagulability: an atherogenic link? Arterioscler Thromb Vasc Biol 1997; 17: 1780–1785.